Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleNEUROPHARMACOLOGY

Converging Protein Kinase Pathways Mediate Adenylyl Cyclase Superactivation upon Chronic δ-Opioid Agonist Treatment

Eva V. Varga, Marc K. Rubenzik, Dagmar Stropova, Masano Sugiyama, Vanessa Grife, Victor J. Hruby, Kenner C. Rice, William R. Roeske and Henry I. Yamamura
Journal of Pharmacology and Experimental Therapeutics July 2003, 306 (1) 109-115; DOI: https://doi.org/10.1124/jpet.103.049643
Eva V. Varga
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marc K. Rubenzik
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dagmar Stropova
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Masano Sugiyama
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vanessa Grife
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Victor J. Hruby
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kenner C. Rice
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
William R. Roeske
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Henry I. Yamamura
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Adenylyl cyclase (AC) superactivation is thought to play an important role in opioid tolerance, dependence, and withdrawal. In the present study, we investigated the involvement of protein kinases in chronic δ-opioid agonist-mediated AC superactivation in Chinese hamster ovary (CHO) cells stably expressing the human δ-opioid receptor (hDOR/CHO). Maximal forskolin-stimulated cAMP formation in hDOR/CHO cells increased by 472 ± 91, 399 ± 2, and 433 ± 73% after chronic treatment with the δ-opioid agonists (+)-4-[(αR)-α-((2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl)-3-methoxy-benzyl]-N,N-diethyl benzamide (SNC 80), [d-Pen2,d-Pen5]-enkephalin, and deltorphin II, respectively. Concurrently, chronic SNC 80 (1 μM, 4-h) treatment augmented 32P incorporation into a 200-kDa protein immunoreactive with the ACV/VI antibody by 300 ± 60% in hDOR/CHO cell lysates. The calmodulin antagonist calmidazolium significantly attenuated chronic deltorphin II-mediated AC superactivation. Tyrosine kinase (genistein) and protein kinase C (chelerythrine) inhibitors individually had minimal effect on chronic δ-opioid agonist-mediated AC superactivation. Conversely, simultaneous treatment with both genistein and chelerythrine significantly attenuated AC superactivation. Because we showed previously that the Raf-1 inhibitor 3-(3,5-dibromo-4-hydroxybenzylidene-5-iodo-1,3-dihydro-indol-2-one (GW5074) attenuates AC superactivation, we hypothesize that parallel calmidazolium-, chelerythrine-, and genistein-sensitive pathways converge at Raf-1 to mediate AC superactivation by phosphorylating AC VI in hDOR/CHO cells.

Footnotes

  • This work was supported in part by grants from the National Institutes of Health and the Arizona Disease Control Research Commission.

  • DOI: 10.1124/jpet.103.049643.

  • ABBREVIATIONS: AC, adenylyl cyclase; CHO, Chinese hamster ovary; hDOR, human δ-opioid receptor; GW5074, 3-(3,5-dibromo-4-hydroxybenzylidene-5-iodo-1,3-dihydro-indol-2-one; MAPK, mitogen-activated protein kinase; SNC 80, (+)-4-[(αR)-α-((2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl)-3-methoxy-benzyl]-N,N-diethyl benzamide; DPDPE, [d-Pen2-d-Pen5]-enkephalin; IMDM: Iscove's modified Dulbecco's medium; PAGE, polyacrylamide gel electrophoresis; ANOVA, analysis of variance; PKC, protein kinase C; LMMP, longitudinal muscle myenteric plexus; H-89, N-[2-((p-bromocinnamyl)amino)ethyl]-5-isoquinoline sulfonamide, 2HCl; IP1, inositol phosphate-1.

    • Received January 27, 2003.
    • Accepted March 20, 2003.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 306 (1)
Journal of Pharmacology and Experimental Therapeutics
Vol. 306, Issue 1
1 Jul 2003
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Converging Protein Kinase Pathways Mediate Adenylyl Cyclase Superactivation upon Chronic δ-Opioid Agonist Treatment
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleNEUROPHARMACOLOGY

Converging Protein Kinase Pathways Mediate Adenylyl Cyclase Superactivation upon Chronic δ-Opioid Agonist Treatment

Eva V. Varga, Marc K. Rubenzik, Dagmar Stropova, Masano Sugiyama, Vanessa Grife, Victor J. Hruby, Kenner C. Rice, William R. Roeske and Henry I. Yamamura
Journal of Pharmacology and Experimental Therapeutics July 1, 2003, 306 (1) 109-115; DOI: https://doi.org/10.1124/jpet.103.049643

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleNEUROPHARMACOLOGY

Converging Protein Kinase Pathways Mediate Adenylyl Cyclase Superactivation upon Chronic δ-Opioid Agonist Treatment

Eva V. Varga, Marc K. Rubenzik, Dagmar Stropova, Masano Sugiyama, Vanessa Grife, Victor J. Hruby, Kenner C. Rice, William R. Roeske and Henry I. Yamamura
Journal of Pharmacology and Experimental Therapeutics July 1, 2003, 306 (1) 109-115; DOI: https://doi.org/10.1124/jpet.103.049643
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Iclepertin (BI 425809) in schizophrenia-related models
  • D1 agonist vs. methylphenidate on PFC working memory
  • Obesity Thwarts Preconditioning in TBI
Show more Neuropharmacology

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2022 by the American Society for Pharmacology and Experimental Therapeutics